Companies consider delaying reimbursement submissions in Australia
This article was originally published in Scrip
Executive Summary
Some 11 companies are now considering delaying submissions to Australia's reimbursement scientific committee, PBAC, after the federal government recently decided to defer listing new medicines on the Pharmaceutical Benefits Scheme, says Medicines Australia, which represents the pharmaceutical industry. The products at risk of delay included oncology, cardiovascular, respiratory, mental health and diabetic medicines.